高速液体クロマトグラフィーによる血清中メソトレキセート及び主代謝物7-ヒドロキシメソトレキセートの高感度定量法
スポンサーリンク
概要
- 論文の詳細を見る
Recently, methotrexate (MTX) low dose therapy (5-10 mg/m^2) has been used for the treatment of patients with rheumatoid arthritis. Hence a practical and sensitive high-performance liquid chromatographic method for the determination of MTX and its main metabolite 7-hydroxymethotrexate (7-OH-MTX) in human serum has been studied. After deproteinization with perchloric acid followed by the addition of pH 5.0 acetate buffer, the serum sample was purified by solid-phase extraction on a Sep-Pak C_<18> cartridge. The analyte was chromatographed on a reversed-phase Inertsil ODS-2 column using a phosphate buffer-acetonitrile at pH 3.0 system as the mobile phase, and the effluent from the column was monitored at 303 nm. Gradient elution was employed to increase the sensitivity for 7-OH-MTX. A good linear relationship between peak height and concentration was found for the two compounds in the range 2.5 to 100 ng/ml of the human serum, and the detection limits were about 1 ng/ml for the two compounds. The day-to-day coefficients of variation assay were 2.3% (20 ng/ml) and 4.4% (100 ng/ml) for MTX and 4.6% (20 ng/ml) for 7-OH-MTX. The present method was successfully applied to the analysis of the serum after a single oral administration of MTX 2.5 mg tablet to male dogs. MTX was rapidly absorbed, reached to the maximal level at about 1.4h and thereafter decreased monoexponentially with a half-life of about 1.4h. A metabolite, 7-OH-MTX was not detected in the serum up to 24h post dose.
- 公益社団法人日本薬学会の論文
- 1994-08-25
著者
-
井上 義敬
日本レダリー株式会社製薬製剤研究所
-
井上 義敬
日本レダリー(株)製薬製剤研究所
-
北村 正孝
日本レダリー(株)製薬製剤研究部
-
平井 利生
日本レダリー(株)製薬製剤研究所
-
北村 正孝
日本レダリー(株)製薬製剤研究所
関連論文
- 抗炎症薬ビフェニル酢酸の直腸投与における薬物担体としての水溶性β-シクロテキストリン誘導体の有効利用
- LS-007投与後の歯周ポケット内ミノサイクリン濃度 : 第30回春季日本歯周病学会総会
- LS-O07投与後の歯周ポケット内ミノサイクリン濃度
- 高速液体クロマトグラフィーによる血清中メソトレキセート及び主代謝物7-ヒドロキシメソトレキセートの高感度定量法
- 蛍光検出高速液体クロマトグラフィーによる血清中N-ソラネシル-N, N'-ビス(3,4-ジメトキシベンジル)エタンジアミンの定量
- 二級アミンを含む新規イソプレノイド誘導体の高速液体クロマトグラフィーにおける高感度検出のための蛍光誘導体化試薬サクシニミド-2-フルオレニルカルバメートの開発